Marc Peeters

2 ta ish

Antwerp University Hospital

1. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

   Eric Van Cutsem, Fernando Rivera, Scott Berry +9

   MaqolaOAOchiq kirish20092 iqtibos

   ABIABI:AkademIndex/2026.other.237787

2. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

   Giuseppe Bronte, Nicola Silvestris, Marta Castiglia +10

   Sharh maqolaOAOchiq kirish20152 iqtibos

   ABIABI:AkademIndex/2026.other.241881